M.I.TECH Co (179290) Fair Value & Analysis
Healthcare · KR · Market cap 146B KRW
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 21 days ago
Share price +22.3% over the past month.
A solid business, screening 30% undervalued on our models.
What matters now
- The rarer combination: high quality (70/100) AND below fair value. That earns a closer look rather than a quick verdict.
- A fairly wide model range (5,253 KRW to 11,981 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 3,942 KRW – 15,151 KRW · fair‑value band 5,253 KRW – 11,981 KRW · the 5,370 KRW price screens below the 7,004 KRW fair value. Dashed = 300-day average. As of Jul 20, 2026.
Analysis
M.I.TECH Co (179290) currently trades at 5,370 KRW, while our model-based Fair Value estimate is 7,004 KRW, implying the stock looks roughly 30.4% undervalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, M.I.TECH Co generated revenue of 66.6B KRW at a net margin of 29.1%. Revenue declined 3.0% year over year. It earns a return on equity of 16.4%. Fundamentals as of Jul 20, 2026
Our scenario range runs from 5,253 KRW (bear case) to 11,981 KRW (bull case); at 5,370 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high and 24% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 30%, 179290 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (11,986 KRW) versus Asset-Based (2,607 KRW). Highest evidence: Growth DCF (80).
Notify me when 179290 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 68 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
M.I.TECH Co.,Ltd engages in the provision of various medical devices in South Korea. The company offers HANAROSTENT, a non-vascular stent; and glucometers under the GBIO BASE and RAPICHECK brand names.
Full company description
M.I.TECH Co.,Ltd engages in the provision of various medical devices in South Korea. The company offers HANAROSTENT, a non-vascular stent; and glucometers under the GBIO BASE and RAPICHECK brand names. It also provides beauty systems, such as BRT system which is used in cleansing skin and inject the effective component in non-invasive way; and ClearView which is used in injecting the effective component in non-invasive way and instantly check skin condition before and after treatment. The company was formerly known as Solco Intermed Co., Ltd. and changed its name to M.I.TECH Co.,Ltd in March 1999. M.I.TECH Co.,Ltd was founded in 1991 and is headquartered in Pyeongtaek-Si, South Korea. M.I.TECH Co.,Ltd operates as a subsidiary of Synergy Innovation Co., Ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
M.I.TECH Co reported revenue of 67.2B KRW in FY2025 versus 50.3B KRW in FY2021, a compound +7.5%/yr. Reported net income was 20.3B KRW in FY2025, compounding +13.5%/yr from FY2021.
Watch 179290: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare M.I.TECH Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is M.I.TECH Co (179290) overvalued or undervalued?
What is the fair value of 179290?
What is the quality score of 179290?
What is the revenue of M.I.TECH Co (179290)?
What is the net profit margin of 179290?
Does M.I.TECH Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track M.I.TECH Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.